TIDMNSCI
NetScientific PLC
27 May 2022
RNS REACH
NetScientific plc
("NetScientific", the "Group" or the "Company")
PDS Biotech presents new data for two ongoing clinical
trials
NetScientific plc (AIM: NSCI), the international life sciences
and sustainability technology investment and commercialisation
Group, announces that its portfolio company, PDS Biotechnology
Corporation (Nasdaq: PDSB), has provided updates for two their
ongoing Phase 2 clinical trials, ahead of presentations at the ASCO
2022 oncology research conference on 6 June 2022.
Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical
Trial in Recurrent or Metastatic Head and Neck Cancer at ASCO
2022:
Highlights:
-- 76.5% of patients had either disease stabilization or tumour shrinkage
-- 89% of patients alive at median 9 months suggesting survival benefit
-- Combination treatment well tolerated to date. 94% of patients
received 4/5 PDS0101 doses with no treatment-related grade 3 or
higher adverse events
The VERSATILE-002 trial is a single-arm Phase 2 study evaluating
the safety and efficacy of PDS0101, an HPV16-targeted
immunotherapy, leveraging PDS Biotech's proprietary Versamune(R)
technology, in combination with Merck's anti-PD-1 therapy
KEYTRUDA(R). The combination is being evaluated in checkpoint
inhibitor (CPI) -naïve and CPI-refractory patients with
recurrent/metastatic HPV16-positive head and neck squamous cell
carcinoma (HNSCC).
Preliminary data from first 19 patients treated with PDS0101 in
combination with KEYTRUDA(R) (pembrolizumab) demonstrates 41%
response rate thus far for first line recurrent or metastatic head
and neck cancer, in comparison to the published results of
approximately 19% for approved checkpoint inhibitors used as
monotherapy. After 9 months the overall survival rate was 87.2%;
whilst progression free survival was 55.2%.
https://bit.ly/3wTxu9O
Presentation of Data from NCI-Led Triple Combination Phase 2
Clinical Trial in Advanced, Refractory HPV-Positive Cancers at ASCO
2022:
Highlights:
-- 77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months
-- 75% of CPI naïve patients alive at median follow up of 17 months
-- Anti-tumour objective responses seen in 88% of CPI naïve
patients and 63% CPI refractory patients (high dose of M9241)
-- Study shows early evidence of durable clinical responses
The Phase 2 triple combination trial (NCT04287868) is evaluating
the safety and efficacy of PDS0101, an investigational
HPV16-targeted immunotherapy, in combination with two
investigational immune-modulating agents.
The triple combination is being studied in CPI-naïve and
-refractory patients with advanced HPV-positive anal, cervical,
head and neck, vaginal, and vulvar cancers who have failed prior
therapy. Objective response is measured by radiographic tumour
responses. Early data from the study suggests that the triple
combination is preferentially active in HPV16-positive cancer.
Combinations of CPI and chemotherapy are being evaluated in
refractory HPV-associated cancers. For most patients with CPI
refractory HPV-associated disease, there is no clear effective
standard of care therapy. Data strongly suggests, in agreement with
the published preclinical studies, that all 3 drugs contribute to
the clinical outcomes.
https://bit.ly/3wV5amv
Dr. Ilian Iliev, CEO of NetScientific, added:
"These are early results, which nevertheless provide real world
- and positive - evidence from PDS's Phase 2 trials. The positive
results from two parallel trials support the company's thesis that
Versamune(R) is a platform applicable in multiple clinical
applications. We look forward to the ASCO presentation and further
results by the company."
For more information, please contact:
NetScientific Via Walbrook PR
Ilian Iliev, CEO
WH Ireland (NOMAD, Financial Adviser
and Broker)
Chris Fielding / Darshan Patel +44 (0)20 7220 1666
Walbrook PR +44 (0)20 7933 8780 or netscientific@walbrookpr.com
Nick Rome / Tom Cooper 07748 325 236 / 07971 221 972
About NetScientific
NetScientific plc (AIM: NSCI) is a holding company, that invests
in, develops, commercialises and realises shareholder value in life
sciences/healthcare, sustainability and technology companies, which
offer significant growth potential predominately in the UK, EU and
USA.
With the acquisition of EMV Capital in August 2020 and further
investment activities, the Group more than doubled its portfolio
from 8 to 22 companies. These are held as direct subsidiary and
minority stakes, through balance sheet investment or capital under
advisory, varying from start-up private companies to publicly
listed equities.
NetScientific delivers shareholder returns through a proactive
and hands-on management approach to their portfolio companies;
identifying, investing in, and helping to build game-changing
companies. The Group targets value inflection points and the
release of value through partial or full exits from trade sales,
public listings, or equity sales. The Company has a strong
transatlantic and growing international presence, providing
attractive expansion prospects.
NSCI can deploy a capital-light investment structure; utilising
the power of the PLC Brand, and the NetScientific balance sheet to
anchor future investments and achieve a multiplier effect by
attracting 3rd party investment for the portfolio companies.
NetScientific is headquartered in London, United Kingdom, and
was admitted to trading on AIM, a market operated by the London
Stock Exchange, in 2013 (website: netscientific.net ).
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFZGZKFNKGZZM
(END) Dow Jones Newswires
May 27, 2022 09:39 ET (13:39 GMT)
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Netscientific (LSE:NSCI)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
